Some issues of methotrexate pneumonitis in rheumatoid arthritis


DOI: https://dx.doi.org/10.18565/pharmateca.2019.11.69-72

D.V. Bestaev (1), S.A. Ktsoeva (1), Z.S. Brtsieva (1), L.M. Khutieva (1), L.V. Osipova (1), N.N. Burduli (1), O.T. Kotsoeva (1), T.D. Bestaeva (2)

1) North Ossetian State Medical Academy (NOSMA), Vladikavkaz, Russia; 2) Family Medicine Clinic, Vladikavkaz, Russia
Rheumatoid arthritis (RA) is a systemic autoimmune rheumatic disease with a wide range of extraarticular manifestations along with joint damage. Extraarticular manifestations of RA include pulmonary pathology (PP). The development of PP in patients with RA can by directly influenced by the course of the disease, infection, as well as therapy with disease-modifying antirheumatic drugs (DMARDs). The “gold” standard for RA therapy includes treatment with methotrexate. The article provides an overview of recent studies in the field of studying the role of methotrexate in the development of PP in patients with RA.
Keywords: rheumatoid arthritis, methotrexate, pulmonary pathology

About the Autors


Corresponding author: David V. Bestaev, MD, Head of the Department of Internal Diseases № 3, North Ossetian State Medical Academy (NOSMA), Vladikavkaz, Russia; e-mail: davidbestaev@rambler.ru; Scopus Author ID: https://www.scopus.com/authid/detail.uri?authorId=55799416300; ORCID: https://orcid.org/0000-0001-7051-067X 
Address: 40, Pushkinskaya Street, Vladikavkaz 362019, Russian Federation


Бионика Медиа